Literature DB >> 27499138

Rictor has a pivotal role in maintaining quiescence as well as stemness of leukemia stem cells in MLL-driven leukemia.

Y Fang1,2, Y Yang1,2, C Hua3, S Xu1,2, M Zhou1,2, H Guo3, N Wang1,2, X Zhao1, L Huang1,2, F Yu1,2, H Cheng3, M L Wang4, L Meng1,2, T Cheng3, W Yuan3, D Ma2, J Zhou1,2.   

Abstract

Little is known about the roles of Rictor/mTORC2 in the leukemogenesis of acute myeloid leukemia. Here, we demonstrated that Rictor is essential for the maintenance of mixed lineage leukemia (MLL)-driven leukemia by preventing leukemia stem cells (LSCs) from exhaustion. Rictor depletion led to a reactive activation of mTORC1 signaling by facilitating the assembly of mTORC1. Hyperactivated mTORC1 signaling in turn drove LSCs into cycling, compromised the quiescence of LSCs and eventually exhausted their capacity to generate leukemia. At the same time, loss of Rictor had led to a reactive activation of FoxO3a in leukemia cells, which acts as negative feedback to restrain greater over-reactivation of mTORC1 activity and paradoxically protects leukemia cells from exhaustion. Simultaneous depletion of Rictor and FoxO3a enabled rapid exhaustion of MLL LSCs and a quick eradication of MLL leukemia. As such, our present findings highlighted a pivotal regulatory axis of Rictor-FoxO3a in maintaining quiescence and the stemness of LSCs.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27499138     DOI: 10.1038/leu.2016.223

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  36 in total

1.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

2.  mTORC1 is essential for leukemia propagation but not stem cell self-renewal.

Authors:  Takayuki Hoshii; Yuko Tadokoro; Kazuhito Naka; Takako Ooshio; Teruyuki Muraguchi; Naoyuki Sugiyama; Tomoyoshi Soga; Kimi Araki; Ken-Ichi Yamamura; Atsushi Hirao
Journal:  J Clin Invest       Date:  2012-05-24       Impact factor: 14.808

3.  Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells.

Authors:  Takayuki Hoshii; Atsuo Kasada; Tomoki Hatakeyama; Masashi Ohtani; Yuko Tadokoro; Kazuhito Naka; Tsuneo Ikenoue; Tomokatsu Ikawa; Hiroshi Kawamoto; Hans Joerg Fehling; Kimi Araki; Ken-ichi Yamamura; Satoshi Matsuda; Atsushi Hirao
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-24       Impact factor: 11.205

4.  Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.

Authors:  N Sandhöfer; K H Metzeler; M Rothenberg; T Herold; S Tiedt; V Groiß; M Carlet; G Walter; T Hinrichsen; O Wachter; M Grunert; S Schneider; M Subklewe; A Dufour; S Fröhling; H-G Klein; W Hiddemann; I Jeremias; K Spiekermann
Journal:  Leukemia       Date:  2014-10-17       Impact factor: 11.528

5.  PML targeting eradicates quiescent leukaemia-initiating cells.

Authors:  Keisuke Ito; Rosa Bernardi; Alessandro Morotti; Sahoko Matsuoka; Giuseppe Saglio; Yasuo Ikeda; Jacalyn Rosenblatt; David E Avigan; Julie Teruya-Feldstein; Pier Paolo Pandolfi
Journal:  Nature       Date:  2008-05-11       Impact factor: 49.962

6.  Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence.

Authors:  Shoichiro Takeishi; Akinobu Matsumoto; Ichiro Onoyama; Kazuhito Naka; Atsushi Hirao; Keiichi I Nakayama
Journal:  Cancer Cell       Date:  2013-03-18       Impact factor: 31.743

7.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Authors:  Mark A Dawson; Rab K Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C Robson; Chun-wa Chung; Carsten Hopf; Mikhail M Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Soren Beinke; Trevor D Chapman; Emma J Roberts; Peter E Soden; Kurt R Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K Burnett; Phillip Jeffrey; Gerard Drewes; Kevin Lee; Brian J P Huntly; Tony Kouzarides
Journal:  Nature       Date:  2011-10-02       Impact factor: 49.962

8.  Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia.

Authors:  Keunwook Lee; Ki Taek Nam; Sung Hoon Cho; Prathyusha Gudapati; Yoonha Hwang; Do-Sim Park; Ross Potter; Jin Chen; Emmanuel Volanakis; Mark Boothby
Journal:  J Exp Med       Date:  2012-04-02       Impact factor: 14.307

9.  Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis.

Authors:  B Douglas Smith; Dalia Mahmoud; Henry J Henk; Charles L Beach; Laura Weber
Journal:  Exp Hematol Oncol       Date:  2014-03-25

10.  Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression.

Authors:  Jeffrey A Magee; Tsuneo Ikenoue; Daisuke Nakada; Jae Y Lee; Kun-Liang Guan; Sean J Morrison
Journal:  Cell Stem Cell       Date:  2012-09-07       Impact factor: 24.633

View more
  7 in total

1.  Hypoxia favors chemoresistance in T-ALL through an HIF1α-mediated mTORC1 inhibition loop.

Authors:  Lucine Fahy; Julien Calvo; Sara Chabi; Laurent Renou; Charly Le Maout; Sandrine Poglio; Thierry Leblanc; Arnaud Petit; André Baruchel; Paola Ballerini; Irina Naguibneva; Rima Haddad; Marie-Laure Arcangeli; Frederic Mazurier; Francoise Pflumio; Benjamin Uzan
Journal:  Blood Adv       Date:  2021-01-26

Review 2.  Targeting metabolism: A potential strategy for hematological cancer therapy.

Authors:  Xue Tang; Fen Chen; Li-Chun Xie; Si-Xi Liu; Hui-Rong Mai
Journal:  World J Clin Cases       Date:  2022-04-06       Impact factor: 1.534

3.  Decitabine-Induced Changes in Human Myelodysplastic Syndrome Cell Line SKM-1 Are Mediated by FOXO3A Activation.

Authors:  Wen Zeng; Hanjun Dai; Ming Yan; Xiaojun Cai; Hong Luo; Min Ke; Zeming Liu
Journal:  J Immunol Res       Date:  2017-10-16       Impact factor: 4.818

Review 4.  Biological Aspects of mTOR in Leukemia.

Authors:  Simone Mirabilii; Maria Rosaria Ricciardi; Monica Piedimonte; Valentina Gianfelici; Maria Paola Bianchi; Agostino Tafuri
Journal:  Int J Mol Sci       Date:  2018-08-14       Impact factor: 5.923

5.  Non-Thermal Plasma Induces Antileukemic Effect Through mTOR Ubiquitination.

Authors:  Sun-Yong Kim; Hyo Jeong Kim; Haeng Jun Kim; Chul-Ho Kim
Journal:  Cells       Date:  2020-03-02       Impact factor: 6.600

Review 6.  Signaling Pathways Involved in Nutrient Sensing Control in Cancer Stem Cells: An Overview.

Authors:  Martha Robles-Flores; Angela P Moreno-Londoño; M Cristina Castañeda-Patlán
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-22       Impact factor: 5.555

Review 7.  New Insights into the Pathogenesis of Systemic Mastocytosis.

Authors:  Zhixiong Li
Journal:  Int J Mol Sci       Date:  2021-05-05       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.